US2015359804A1PendingUtilityA1

Extended-release drug delivery compositions

Assignee: ORBIS BIOSCIENCES INCPriority: Jun 12, 2014Filed: Jun 12, 2015Published: Dec 17, 2015
Est. expiryJun 12, 2034(~7.9 yrs left)· nominal 20-yr term from priority
A61K 47/32A61K 9/1635A61K 31/43A61K 31/713A61K 31/573A61K 31/711A61K 9/10A61K 47/38A61K 9/0046A61K 47/10A61K 9/0019A61K 47/26A61P 27/16A61K 9/1647A61K 38/38A61K 47/34A61K 9/1641A61K 9/1652A61K 47/14A61K 47/42A61K 47/36
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An extended-release drug delivery composition and method of administering the same is provided. The composition comprises microspheres loaded with a biologically-active agent and suspended in a soluble polymer capable of forming a film upon injection onto a biological surface.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition comprising:
 a soluble polymer, wherein the soluble polymer is from 0.5% to about 10% w/v of the composition;   a carrier liquid, wherein the carrier liquid is able to evaporate at 37° C.; and   a biologically-active agent.   
     
     
         2 . The composition of  claim 1  further comprising a microsphere, wherein the microsphere comprises the biologically-active agent. 
     
     
         3 . The composition of  claim 1  further comprising a plurality of microspheres, wherein the plurality of microspheres comprises the biologically-active agent, and wherein at least 90% of the plurality of microspheres have a particle diameter that does not deviate more than 10% from a mean particle diameter of the plurality of microspheres. 
     
     
         4 . The composition of  claim 4  wherein the mean particle diameter is less than 150 μm. 
     
     
         5 . The composition of  claim 4  wherein the mean particle diameter is from about 30 μm to about 60 μm. 
     
     
         6 . The composition of  claim 1  wherein the soluble polymer is selected from the group consisting of polyvinyl alcohol (PVA), polyvinyl acetate (PVAc), alginate, polyethylene glycol (PEG), hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), eudragits, collagen, and gelatin. 
     
     
         7 . The composition of  claim 1  further comprising a surfactant, wherein the surfactant is selected from the group consisting of polysorbate 20, polysorbate 60, polysorbate 80 or sorbitan laurate. 
     
     
         8 . A composition comprising:
 a means for forming a film on a biological tissue of a human subject; and   a biologically-active agent.   
     
     
         9 . The composition of  claim 11  further comprising a microsphere, wherein the microsphere comprises the biologically-active agent. 
     
     
         10 . The composition of  claim 11  further comprising a plurality of microspheres, wherein the plurality of microspheres comprises the biologically-active agent, and wherein at least 90% of the plurality of microspheres have a particle diameter that does not deviate more than 10% from a mean particle diameter of the plurality of microspheres. 
     
     
         11 . The composition of  claim 11  wherein the mean particle diameter is less than 150 μm. 
     
     
         12 . The composition of  claim 11  wherein the biological tissue is a biological barrier structure. 
     
     
         13 . The composition of  claim 12  wherein the biological barrier structure is the round window membrane. 
     
     
         14 . A method for providing an extended-release treatment to a subject, the method comprising the step of injecting a composition onto a biological tissue of a subject, wherein the composition comprises:
 a means for forming a film on the biological tissue; and   a biologically-active agent.   
     
     
         15 . The method of  claim 14  wherein the composition further comprises a plurality of microspheres, wherein the plurality of microspheres comprises the biologically-active agent, and wherein at least 90% of the plurality of microspheres have a particle diameter that does not deviate more than 10% from a mean particle diameter of the plurality of microspheres. 
     
     
         16 . The method of  claims 15  wherein the mean particle diameter is less than 150 μm. 
     
     
         17 . The method of  claim 14  wherein the biological tissue is a biological barrier structure. 
     
     
         18 . The method  claim 17  wherein the biological barrier structure is the round window membrane of the inner ear. 
     
     
         19 . The method of  claim 18  wherein the step of injecting the composition is performed by an intratympanic injection. 
     
     
         20 . The method of  claim 14  wherein the biological tissue is the round window membrane and the subject is suffering from sensorineural hearing loss, and wherein the biologically-active agent is a therapeutic compound used in the treatment of sensorineural hearing loss.

Join the waitlist — get patent alerts

Track US2015359804A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.